GetTopicDetailResponse(id=b633108840b8, topicName=axi-cel, introduction=axi-cel, content=axi-cel 復發(fā)難治性大B細胞淋巴瘤, image=null, comments=0, allHits=862, url=null, type=1, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Tue Dec 19 15:31:01 CST 2023, time=2023-12-19, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=472413, tagList=[TagDto(tagId=472413, tagName=axi-cel)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2256370, encodeId=2cdd22563e0f6, content=<a href='/topic/show?id=4fa110931ac' target=_blank style='color:#2F92EE;'>#liso-cel#</a> <a href='/topic/show?id=b633108840b8' target=_blank style='color:#2F92EE;'>#axi-cel#</a>, objectTitle=【Haematologica】liso-cel對比axi-cel的真實世界研究, objectType=article, longId=867432, objectId=7dc186e43211, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240510/1715353013387_5579292.jpg, objectUrl=/article/show_article.do?id=7dc186e43211, replyNumber=0, likeNumber=34, createdTime=2025-03-16, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=7dc186e43211, moduleTitle=【Haematologica】liso-cel對比axi-cel的真實世界研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=7dc186e43211)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226388, encodeId=e63f22263880a, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a> <a href='/topic/show?id=b633108840b8' target=_blank style='color:#2F92EE;'>#axi-cel#</a> <a href='/topic/show?id=206e112102dd' target=_blank style='color:#2F92EE;'>#復發(fā)/難治性大B細胞淋巴瘤#</a>, objectTitle=【JCO】axi-cel治療LBCL 5年隨訪，29%的患者持續(xù)緩解, objectType=article, longId=843638, objectId=ff29843638e4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240905/1725521610942_8538692.jpg, objectUrl=/article/show_article.do?id=ff29843638e4, replyNumber=0, likeNumber=78, createdTime=2024-09-18, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ff29843638e4, moduleTitle=【JCO】axi-cel治療LBCL 5年隨訪，29%的患者持續(xù)緩解, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=ff29843638e4)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2175883, encodeId=ab5921e5883c3, content=<a href='/topic/show?id=b633108840b8' target=_blank style='color:#2F92EE;'>#axi-cel#</a> <a href='/topic/show?id=80d2108841bf' target=_blank style='color:#2F92EE;'>#復發(fā)難治性大B細胞淋巴瘤#</a>, objectTitle=【Blood Adv】axi-cel治療LBCL的橋接治療不影響生存：美國淋巴瘤CART聯(lián)盟研究, objectType=article, longId=805533, objectId=0948805533c7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-staff-meeting-GXNVP9J.jpg, objectUrl=/article/show_article.do?id=0948805533c7, replyNumber=0, likeNumber=106, createdTime=2023-12-19, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0948805533c7, moduleTitle=【Blood Adv】axi-cel治療LBCL的橋接治療不影響生存：美國淋巴瘤CART聯(lián)盟研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=0948805533c7)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2023-12-19發(fā)表于上海
